Cabaletta Bio Inc Market Cap ($240.75 Million)
Market Cap & Net Worth: Cabaletta Bio Inc (CABA)
Cabaletta Bio Inc market cap. Cabaletta Bio Inc (NASDAQ:CABA) has a market capitalization of $240.75 Million ($240.75 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15605 globally and #3725 in its home market, demonstrating a 5.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cabaletta Bio Inc's stock price $1.42 by its total outstanding shares 169545445 (169.55 Million). Also see Cabaletta Bio Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Cabaletta Bio Inc Market Cap History (2019–2026)
Cabaletta Bio Inc market cap history from 2019 to 2026. Data shows change from $2.37 Billion to $240.75 Million (-24.24% CAGR). Check Cabaletta Bio Inc (CABA) share price today for real-time trading data and today's change.
Index Memberships
Cabaletta Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #418 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1528 of 3165 |
Weight: Cabaletta Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cabaletta Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cabaletta Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cabaletta Bio Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
211592715360.00x
Cabaletta Bio Inc's market cap is 211592715360.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.12 Billion | $0.01 | -$32.49 Million | 211592715360.00x | N/A |
Competitor Companies of CABA by Market Capitalization
Companies near Cabaletta Bio Inc in the global market cap rankings as of November 4, 2026. Also see CABA current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Cabaletta Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Cabaletta Bio Inc (2019–2026)
Market capitalization of Cabaletta Bio Inc from 2019 to today. Between 2019 and today, Cabaletta Bio Inc's market cap moved from $2.37 Billion to $ 240.75 Million, with a yearly change of -24.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $240.75 Million | -35.16% |
| 2025 | $371.30 Million | -3.52% |
| 2024 | $384.87 Million | -90.00% |
| 2023 | $3.85 Billion | +145.41% |
| 2022 | $1.57 Billion | +144.06% |
| 2021 | $642.58 Million | -69.63% |
| 2020 | $2.12 Billion | -10.67% |
| 2019 | $2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cabaletta Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $240.75 Million USD |
| MoneyControl | $240.75 Million USD |
| MarketWatch | $240.75 Million USD |
| marketcap.company | $240.75 Million USD |
| Reuters | $240.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase synd… Read more